7-(2-Methyl-4,5-diphenylimidazol-1-yl)heptanoic acid | 474429-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 7-(2-Methyl-4,5-diphenylimidazol-1-yl)heptanoic acid
• CAS: 474429-84-0
• 化学式: C₂₃H₂₆N₂O₂
• 分子量: 362.472
• InChiKey: WCOYQHBPQYYEBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-(2-Methyl-4,5-diphenylimidazol-1-yl)heptanoic acid 、 2-氟苯酚 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 甲苯 为溶剂， 生成 [6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamic acid 2-fluorophenyl ester
  参考文献：
  名称：

  Novel inhibitors of fatty acid amide hydrolase

  摘要：

  A class of bisarylimidazole derivatives are identified as potent inhibitors of the enzyme fatty acid amide hydrolase (FAAH). Compound 17 (IC50 = 2 nM) dose-dependently (0.1-10 mg/kg, iv) potentiates the effects of exogenous anandamide (1 mg/kg, iv) in a rat thermal escape test (Hargreaves test), and shows robust antinociceptive activity in animal models of persistent (formalin test) and neuropathic (Chung model) pain. Compound 17 (20 mg/kg, iv) demonstrates activity in the formalin test that is comparable to morphine (3 mg/kg, iv), and is dose-dependently inhibited by the CB1 antagonist SR141716A. In the Chung model, compound 17 shows antineuropathic effects similar to high-dose (100 mg/kg) gabapentin. FAAH inhibition shows potential utility for the clinical treatment of persistent and neuropathic pain. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.009
• 作为产物：
  描述：

  2-methyl-4,5-diphenyl-1H-imidazole 在 sodium hydroxide 、 sodium hydride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 7-(2-Methyl-4,5-diphenylimidazol-1-yl)heptanoic acid
  参考文献：
  名称：

  Novel inhibitors of fatty acid amide hydrolase

  摘要：

  A class of bisarylimidazole derivatives are identified as potent inhibitors of the enzyme fatty acid amide hydrolase (FAAH). Compound 17 (IC50 = 2 nM) dose-dependently (0.1-10 mg/kg, iv) potentiates the effects of exogenous anandamide (1 mg/kg, iv) in a rat thermal escape test (Hargreaves test), and shows robust antinociceptive activity in animal models of persistent (formalin test) and neuropathic (Chung model) pain. Compound 17 (20 mg/kg, iv) demonstrates activity in the formalin test that is comparable to morphine (3 mg/kg, iv), and is dose-dependently inhibited by the CB1 antagonist SR141716A. In the Chung model, compound 17 shows antineuropathic effects similar to high-dose (100 mg/kg) gabapentin. FAAH inhibition shows potential utility for the clinical treatment of persistent and neuropathic pain. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.009

文献信息

• USRE39634E1
  申请人：——

  公开号：USRE39634E1

  公开（公告）日：2007-05-15